• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Evolent Health Appoints Seth R. Frank as Vice President, Investor Relations

    12/1/21 8:00:00 AM ET
    $EVH
    $HNGR
    $MDRX
    Other Consumer Services
    Consumer Discretionary
    Medical Specialities
    Health Care
    Get the next $EVH alert in real time by email

    WASHINGTON, Dec. 1, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Seth R. Frank has joined the company as Vice President, Investor Relations, effective immediately. Reporting to John Johnson, Evolent's Chief Financial Officer, Seth will lead Evolent's investor relations (IR) strategy and oversee its relationships with the investment community.

    "Seth provides a demonstrated track record of proactive, finance-driven leadership in health care investor relations to Evolent," said Evolent Health Chief Financial Officer John Johnson. "He brings long-term relationships with institutional investors, analysts and other stakeholders across the health care services sector, as well as health care information technology specifically. With his expertise in originating strategic IR programs, we anticipate Seth will accelerate the investment community's knowledge of Evolent's business as we continue to deliver on our strategy to create long-term value for shareholders." 

    Seth joins Evolent from Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic services, where he served as Vice President of Treasury and Investor Relations for nearly four years. Previously, Seth was Vice President of Investor Relations at Allscripts (NASDAQ:MDRX), a health care information technology company, for nearly eight years; prior to that, Seth worked in several other investor relations and financial communications roles. Prior to beginning his corporate career in 2006, Seth was an equity analyst and capital markets professional at several firms including Morgan Stanley, SunTrust and A.G. Edwards where he covered the health care information technology, distribution and medical technology industries. Seth received his undergraduate degree from Emory University, an M.S. as a Physician Assistant from the University of Colorado School of Medicine, and also attended the Master of Public Health program at Yale University. He holds the Investor Relations Charter (IRC®) from the National Investor Relations Institute. 

    Evolent Health Logo (PRNewsfoto/Evolent Health)

    About Evolent Health

    Evolent Health (NYSE:EVH) delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management, and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance's Population Health Program Accreditation, and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.

    CONTACTS:

    Investors:

    Seth R. Frank

    Vice President, Investor Relations

    Evolent Health, Inc.

    sfrank@evolenthealth.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-health-appoints-seth-r-frank-as-vice-president-investor-relations-301434968.html

    SOURCE Evolent Health

    Get the next $EVH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVH
    $HNGR
    $MDRX

    CompanyDatePrice TargetRatingAnalyst
    Evolent Health Inc
    $EVH
    11/13/2025$7.00Equal-Weight → Overweight
    Stephens
    Evolent Health Inc
    $EVH
    11/13/2025$7.00Outperform
    BMO Capital Markets
    Evolent Health Inc
    $EVH
    1/10/2025$15.00Buy
    Needham
    Evolent Health Inc
    $EVH
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    Evolent Health Inc
    $EVH
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    Evolent Health Inc
    $EVH
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    Evolent Health Inc
    $EVH
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    Evolent Health Inc
    $EVH
    4/22/2024$40.00Buy
    Citigroup
    More analyst ratings

    $EVH
    $HNGR
    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026

    WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to th

    2/4/26 11:02:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Veradigm Extends Stockholder Rights Plan

    Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan to December 31, 2026 (the "Rights Plan"). The Board's decision to extend the Rights Plan is based on its determination that many of the underlying risks and conditions that existed upon the initial adoption of the Rights Plan will continue to be present beyond February 20, 2026. Accordingly, the Rights Plan is being extended to continue to ensure that all Veradigm stockholders have the opportunity to realize the full potential value of their in

    2/2/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent Practices

    New AI-driven application helps Revenue Cycle Services clients gain faster, clearer visibility into financial performance Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced the launch of a new AI-enabled application for Veradigm Revenue Cycle Services (RCS) clients, designed to deliver faster, deeper revenue cycle insights and strengthen the value of ongoing performance reviews for independent practices. Independent practices continue to face rising administrative complexity and financial pressure, driven by denials, payment variability, staffing constraints, and limited analytic visibility into what is driving rev

    1/28/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    $EVH
    $HNGR
    $MDRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    2/5/26 1:23:13 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form 8-A12G/A filed by Veradigm Inc.

    8-A12G/A - Veradigm Inc. (0001124804) (Filer)

    2/2/26 4:47:45 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Regulation FD Disclosure

    8-K - Veradigm Inc. (0001124804) (Filer)

    2/2/26 4:23:23 PM ET
    $MDRX
    EDP Services
    Technology

    $EVH
    $HNGR
    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $EVH
    $HNGR
    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $EVH
    $HNGR
    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Director Smith Jill D. was granted 23,137 shares (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    1/6/26 4:10:35 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Chief Financial Officer Ramos Mario was granted 587,500 shares (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    1/5/26 4:13:26 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    New insider Ramos Mario claimed no ownership of stock in the company (SEC Form 3)

    3 - Evolent Health, Inc. (0001628908) (Issuer)

    1/5/26 4:10:53 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:20:54 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:18:12 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Health upgraded by Stephens with a new price target

    Stephens upgraded Evolent Health from Equal-Weight to Overweight and set a new price target of $7.00

    11/13/25 9:38:39 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    BMO Capital Markets initiated coverage on Evolent Health with a new price target

    BMO Capital Markets initiated coverage of Evolent Health with a rating of Outperform and set a new price target of $7.00

    11/13/25 9:13:18 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Needham initiated coverage on Evolent Health with a new price target

    Needham initiated coverage of Evolent Health with a rating of Buy and set a new price target of $15.00

    1/10/25 7:49:47 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HNGR
    $MDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Veradigm Appoints Tehsin Syed as Chief Product and Technology Officer

    Healthcare IT Veteran - former AWS and Cerner senior executive - to lead and accelerate innovation across Veradigm's unique footprint Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today appoints Tehsin Syed, a healthcare technology leader with over two decades of experience, as Chief Product and Technology Officer. Syed most recently served as General Manager, AWS Health AI (Amazon Web Services). Under his leadership, the organization scaled as a growth engine, with net-new products for ambient clinical documentation, genomics, and medical imaging, and interoperability elevated to enterprise grade - capabilities trusted by providers, payers, bioph

    11/3/25 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Privia Health Expands Value-Based Care Footprint with Acquisition of Accountable Care Organization Business from Evolent Health

    ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH). The ACO business cares for over 120,000 attributed lives through the Medicare Shared Savings Program (MSSP), as well as various commercial and Medicare Advantage programs. With this transaction, Privia Health will now serve approximately 1.5 million attributed lives in value-based care (VBC) arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Privia Health will pay $100 million in cash at closing and up to an additional $13 million su

    9/23/25 4:10:00 PM ET
    $EVH
    $PRVA
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    $EVH
    $HNGR
    $MDRX
    Financials

    Live finance-specific insights

    View All

    Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026

    WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to th

    2/4/26 11:02:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Announces Third Quarter 2025 Results

    Q3 2025 financial results ahead of expectations.Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.Expands leadership team to support accelerating growth.WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We are happy to deliver a strong quarter, in the top half of our guidance for both Ad

    11/6/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, Oct. 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    10/9/25 8:30:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HNGR
    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veradigm Inc.

    SC 13G - Veradigm Inc. (0001124804) (Subject)

    11/14/24 4:05:58 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/14/24 1:11:13 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary